HSP90B1 and breast carcinoma: developed a GRP94 monoclonal antibody that interfered with GRP94-dependent HER2 dimerization and phosphorylation in breast cancer and suppressed the HER2+ breast cancer cell growth in vitro and in vivo (57, 78).